Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

J Clin Microbiol. 2021 Mar 19;59(4):e00239-21. doi: 10.1128/JCM.00239-21. Print 2021 Mar 19.

Abstract

INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Laboratories
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Reproducibility of Results
  • Staphylococcal Infections* / drug therapy
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Vancomycin